Close
More
 
back_btn_arrow   Go back
Sign up or login to continue
New to Univadis?
Univadis is a free service for United States Healthcare Professionals.
*Please fill in all required fields.
By clicking "Sign up", I agree to the Terms of Use and Privacy Policy. and attest I am a healthcare professional.
Existing Univadis member:
Sign up or login to continue
Make more time for the moments that matter. Get expertly-curated updates and medical education, instantly.
New to Univadis?
Simply enter a password to join for free, if the information below is correct.
 
*Please enter a valid email address and password.
By clicking "Sign up", I agree to the Terms of Use and Privacy Policy. and attest I am a healthcare professional.
Forgot your password?  Reset now
Existing Univadis member:
Please login to continue
Welcome! Great to have you back.
*Your email address or password is incorrect.
Forgot your password?  Reset now
Reset your password
Please enter your email address, and we will send you a link to reset your password.
*Please enter a valid email address.

is already registered on Univadis

Is this you? Enter your password to continue.
The password you entered is incorrect. Please try again or choose a different option.
Forgot your password?  Reset now
Need more help? Please contact Member Service at support@univadis.com

is already registered on Univadis

Need more help? Please contact Member Service at support@univadis.com
Instructions to create a new password have been sent to the following email address:

For further assistance, please Contact Member Support
Thanks for Registering.
BreadCrumbsIncluded hideAllBreadCrumbs
European Society of Medical Oncology
Barcelona, Spain, September 27 - October 1, 2019
News Coverage
Essential conference news
The Childhood Cancer Survivor Study is a model for late-effect research that offers suggestions for risk reduction interventions
October 03, 2019
As the number of molecular signatures increases, the choice of the right treatment for the right patient becomes a real challenge.
October 03, 2019
Cabazitaxel superior to abiraterone, enzalutamide as a third-line treatment.
October 03, 2019
Largest trial ever on urothelial cancer sees higher response rates with the addition of atezolizumab.
October 03, 2019
Cure rates in oropharyngeal cancer have gone up, but the quality of life in survivors is often compromised by dysphagia and other side effects.
October 03, 2019
But be cautious: longer follow-up is needed to assess the freedom from distant metastases at ten years
October 03, 2019
A French analysis found no correlation between drug price increases and added value.
October 02, 2019
Promising results are emerging, but no strategies are yet available to bring these findings to patients.
October 02, 2019
Final analysis shows modest increase in survival and reduced toxicity compared with chemotherapy.
October 02, 2019
“Practice-changing” study is first success with targeted therapy in this setting.
October 02, 2019
The number of new therapies and biomarkers is rapidly increasing.
October 01, 2019
Studies confirm existing evidence from European populations and are likely to change standard of care in Asia.
October 01, 2019
Promising but still preliminary results from the LIBRETTO-001 global study.
October 01, 2019
First phase 3 trial of pembrolizumab in early TNBC shows promise.
October 01, 2019
Battle of the CDK4/6 inhibitors and an early TNBC breakthrough
October 01, 2019
Combining two types of immune checkpoint inhibitors yields unusually high response rates and prolonged survival in Checkmate 358.
October 01, 2019
The tumour microenvironment could play a pivotal role in immuno-oncology, says Florent Petitprez.
September 30, 2019
Newly published analyses confirm modest benefits, but PD-L1 found to have no influence.
September 30, 2019
Lenvatinib+pembrolizumab seems to prolong PFS regardless of microsatellite instability.
September 30, 2019
Patient frailty relates to poor outcome, with increased risk of treatment intolerance or complications.
September 30, 2019
Study is the first to assess a tailored approach to boosting NIVO treatment with IPI.
September 30, 2019
Should first-line platinum-based chemotherapy be followed by the PARP inhibitor niraparib in advanced ovarian cancer?
September 30, 2019
Beyond BRCA in ovarian cancer?
September 30, 2019
A single centre retrospective study shows durable effects with pembrolizumab.
September 29, 2019
Colorectal cancer: the presence of circulating tumour DNA may indicate which patients should receive extended adjuvant chemotherapy.
September 29, 2019
Surprise result from phase 2 trial comes despite lack of significant improvement on other endpoints.
September 29, 2019
This 5-year analysis represents the longest phase 3 follow-up for any checkpoint inhibitor combination therapy.
September 29, 2019
Strategies to better tailor effective treatments are needed.
September 29, 2019
Patients with a rare disease harbouring rare mutations can be identified and successfully treated.
September 29, 2019
Small study shows encouraging results in heavily pretreated patients.
September 29, 2019
But overall CheckMate-459 results were disappointing and didn’t reach the primary endpoint.
September 29, 2019
Updates incorporate data from the IDEA pooled analysis and other recent studies.
September 27, 2019 -
ESMO guidelines
What is expected at this year’s ESMO?
September 23, 2019
Oncology specialists presented thousands of studies at this year’s ESMO meeting. Univadis journalists chose the most clinically relevant ones and summarized them in our easy-to-scan bullet-point format.

Univadis is a free, time-saving medical news & education community designed exclusively for healthcare professionals. Unique executive summaries tame the onslaught of medical literature and keep clinicians up to date in just a few minutes per day. Concise, interactive educational presentations from our experts help clinicians stay on top of practice-changing research and trends, and collaborate with colleagues at any time, on any device.

Aptus Health does not endorse and is not responsible for the accuracy of the content, or for practices or standards of non-Aptus Health sources.

Copyright © 2019 Aptus Health, Inc. All rights reserved. Version 2.14.541.14

Contact Us

(888) 729-4546
Monday - Friday 8am to 7pm ET

support@univadis.com